Erudio Healtherudio.com
Clinical trial · no report yet · Phase 2
C3NIRA
Cabazitaxel, Carboplatin, and Cetrelimab Followed by Niraparib With or Without Cetrelimab for the Treatment of Aggressive Variant Metastatic Prostate Cancer
- NCT04592237 ↗
- Active, not recruiting
- M.D. Anderson Cancer Center
- Focused
We haven't built an HCP commentary report on C3NIRA (cabazitaxel, cetrelimab and 2 more in Aggressive Variant Prostate Carcinoma) yet. This page shows the registry record and the public commentary we found that names the trial. A report reads that commentary and sets out what clinicians said about the trial, each point linked to its source. How reports are made.
Indexed commentary on C3NIRA so far
Podcasts, YouTube videos and X posts we have indexed that name the trial. It is where a report starts, not where it ends: the build searches for more, so finished reports usually cover more than this.
| Channel | Indexed | |
|---|---|---|
| X threads | 5 | |
| Bluesky threads | 1 |
The trial
ClinicalTrials.gov- Official title
- Randomized Phase II Study of Platinum-Taxane-Cetrelimab Induction Followed by Niraparib Plus or Minus Cetrelimab Maintenance in Men With Aggressive Variant Prostate Cancers
- Phase
- Phase 2
- Status
- Active, not recruiting
- Conditions
- Aggressive Variant Prostate Carcinoma; Castration-Resistant Prostate Carcinoma; Metastatic Prostate Carcinoma; Metastatic Prostate Neuroendocrine Carcinoma; Metastatic Prostate Small Cell Carcinoma; Stage IV Prostate Cancer AJCC v8
- Interventions
- Cabazitaxel; Carboplatin; Cetrelimab; Niraparib
- Arms
- Group I (niraparib) · Experimental
- Group II (cetrelimab, niraparib) · Experimental
- Enrollment
- 120 (estimated)
- Primary outcomes
- Progression-free survival
- Sponsor
- M.D. Anderson Cancer Center with Janssen Pharmaceutica
- Start
- Dec 29, 2020
- Primary completion
- Dec 31, 2027 (estimated)
- Results posted
- No
- Registry record
- NCT04592237 · updated Sep 9, 2026